Nintedanib
Sign in to save this workspacePrimary targets: FGFR1, FGFR2, FGFR3 · FDA status: FDA Approved
Selectivity scorecard
KISS
90.23
Gini
0.608
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Nintedanib. Strongest target: DDR2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 100.0% | 0.0% |
| 2 | LCK | 100.0% | 0.0% |
| 3 | RET | 100.0% | 0.0% |
| 4 | ABL1 | 99.9% | 0.1% |
| 5 | MELK | 99.4% | 0.6% |
| 6 | SIK2 | 99.4% | 0.6% |
| 7 | FLT4_VEGFR3 | 99.2% | 0.8% |
| 8 | MEK5 | 98.6% | 1.4% |
| 9 | PDGFRA | 98.3% | 1.7% |
| 10 | BTK | 98.0% | 2.0% |
| 11 | LYN | 97.9% | 2.1% |
| 12 | YES_YES1 | 97.9% | 2.1% |
| 13 | BLK | 97.6% | 2.4% |
| 14 | FGFR2 | 97.0% | 3.0% |
| 15 | C_SRC | 96.9% | 3.1% |
| 16 | C_KIT | 96.8% | 3.2% |
| 17 | TRKC | 96.7% | 3.3% |
| 18 | KDR_VEGFR2 | 96.4% | 3.6% |
| 19 | DDR1 | 96.1% | 3.9% |
| 20 | PDGFRB | 96.0% | 4.0% |
Selectivity landscape
Where Nintedanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Nintedanib.
Atlas insights for Nintedanib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3751.59 | |
| ALLOGRAFT_REJECTION | 12688.86 | |
| ANDROGEN_RESPONSE | 2757.09 | |
| ANGIOGENESIS | 2235.01 | |
| APICAL_JUNCTION | 12843.57 | |
| APICAL_SURFACE | 1352.03 | |
| APOPTOSIS | 10479.60 | |
| BILE_ACID_METABOLISM | 1327.74 | |
| CHOLESTEROL_HOMEOSTASIS | 1822.59 | |
| COAGULATION | 1467.82 | |
| COMPLEMENT | 7199.69 | |
| DNA_REPAIR | 2602.05 | |
| E2F_TARGETS | 5936.72 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2916.27 | |
| ESTROGEN_RESPONSE_EARLY | 4588.92 | |
| ESTROGEN_RESPONSE_LATE | 4379.27 | |
| FATTY_ACID_METABOLISM | 1192.04 | |
| G2M_CHECKPOINT | 6679.60 | |
| GLYCOLYSIS | 4059.89 | |
| HEDGEHOG_SIGNALING | 1508.79 | |
| HEME_METABOLISM | 2725.70 | |
| HYPOXIA | 5720.51 | |
| IL2_STAT5_SIGNALING | 4297.93 | |
| IL6_JAK_STAT3_SIGNALING | 7358.40 | |
| INFLAMMATORY_RESPONSE | 6691.19 | |
| INTERFERON_ALPHA_RESPONSE | 1186.47 | |
| INTERFERON_GAMMA_RESPONSE | 8715.59 | |
| KRAS_SIGNALING_DN | 1572.48 | |
| KRAS_SIGNALING_UP | 4615.23 | |
| MITOTIC_SPINDLE | 8917.87 | |
| MTORC1_SIGNALING | 5286.50 | |
| MYC_TARGETS_V1 | 4102.45 | |
| MYC_TARGETS_V2 | 1045.14 | |
| MYOGENESIS | 4694.25 | |
| NOTCH_SIGNALING | 332.43 | |
| OXIDATIVE_PHOSPHORYLATION | 1860.68 | |
| P53_PATHWAY | 5278.86 | |
| PANCREAS_BETA_CELLS | 372.99 | |
| PEROXISOME | 1822.99 | |
| PI3K_AKT_MTOR_SIGNALING | 12684.96 | |
| PROTEIN_SECRETION | 2811.76 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 806.26 | |
| SPERMATOGENESIS | 2042.04 | |
| TGF_BETA_SIGNALING | 3178.25 | |
| TNFA_SIGNALING_VIA_NFKB | 6466.05 | |
| UNFOLDED_PROTEIN_RESPONSE | 1986.02 | |
| UV_RESPONSE_DN | 7246.75 | |
| UV_RESPONSE_UP | 4968.36 | |
| WNT_BETA_CATENIN_SIGNALING | 2891.62 | |
| XENOBIOTIC_METABOLISM | 3000.29 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.839 |
| SRR23303752 | — | 0.836 |
| SRR10899984 | — | 0.825 |
| aMVAC.P_005_TURBT_S223 | — | 0.823 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.821 |
Annotations
Sign in to read and post annotations.
Loading…